A 52-WEEK MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, BASKET STUDY WITH AN OPEN-LABEL EXTENSION TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF REMIBRUTINIB (LOU064) IN CHRONIC INDUCIBLE URTICARIA (CINDU) IN ADULTS INADEQUATELY CONTROLLED BY H1-ANTIHISTAMINES (CLOU064M12301)